Clinical Validation

Several peer-reviewed, clinical validation studies illustrate the science behind the Oncotype DX AR-V7 Nucleus Detect® test.

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predective Biomarker for Castration-Resistant Prostate Caner
Scher HI, Graf RP, Schreiber NA.
JAMA Oncol. 2018;4(9):1179-1186. doi:10.1001/jamaoncol.2018.1621.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R.
Eur Urol. 2017 Jun;71(6):874-882. doi: 10.1016/j.eururo.2016.11.024.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP; Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher N, Dittamore R.
JAMA Oncol. 2016;2(11):1441-1449. doi:10.1001/jamaoncol.2016.1828

Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
Antonarakis ES, Changxue L, Luber B
JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
N Engl J Med. 2014; 371: 1028–1038

Additional Related Articles
Making cancer care smarter.®

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.